Clinical Research

BD Biosciences products support a broad range of immunophenotyping and intracellular staining reagents for blood cell disorders and tools for the study of cell cycle, proliferation, and cell death.

Oncology, the study of cancer, is a complex area of human disease with many challenges including heterogeneity of disease and limited samples. Throughout the world, BD Biosciences tools help clinical researchers study genes, proteins, and cells to better understand disease, improve diagnosis and disease management, and facilitate the discovery and development of novel therapeutics. BD Biosciences clinical oncology research solutions range from antibodies to cellular markers for isolation of specific subpopulations, and determination of cytokine expression, transcription factors, and phosphorylation status.


Blood Cell Disorder Research

Leukemias are cancers of the blood or bone marrow characterized by an abnormal proliferation of blood cells, usually white blood cells (leucocytes). Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader group of diseases called hematological neoplasms. BD Biosciences supports leukemia clinical research with a broad range of immunophenotyping and intracellular staining reagents for flow cytometry applications to support scientists looking to understand the biological aspects of these cellular abnormalities. Of particular interest to clinical researchers is the exploration of signaling pathways in leukemic cells and the role of stem cells in blood cancers.

Acute Lymphocytic Leukemia (ALL) research

ALL is a cancer of the blood in which too many lymphocytes, a type of white blood cell, are produced by the bone marrow and by organs of the lymph system.

Acute Myeloid Leukemia (AML) research

AML, also called granulocytic, myelocytic, myeloblastic, or myeloid leukemia, is a cancer of the blood in which too many granulocytes, a type of white blood cell that normally fights infection, are produced in the bone marrow. In addition to overpowering other important cells, these over-produced granulocytes do not mature correctly.

Chronic Lymphocytic Leukemia (CLL) research

CLL is a cancer of the blood in which too many lymphocytes, a type of white blood cell, are produced by the bone marrow and by organs of the lymph system. Normally, the lymphocytes fight infection by making antibodies that attack harmful elements. But in CLL, the cells are immature and overabundant. They crowd out other blood cells, and may collect in the blood, bone marrow, and lymph tissue.

References

Coustan-Smith E, Ribeiro RC, Stow P, et al. A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood. 2006;108:97-102.

Schroers R, Griesinger F, Trümper L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia. 2005;19:750-758.

Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;2:956-964.


Cell Cycle, Proliferation, and Cell Death Research

Cell cycle, proliferation, and cell death play important roles in development and tissue homeostasis. Apoptosis, or programmed cell death, is of particular importance in cancer research. The ability of cells to escape normal apoptotic pathways leads to a survival advantage for malignant cells. In contrast, too much apoptosis contributes to neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. BD Biosciences tools for the study of cell cycle, proliferation, and cell death include BD Pharmingen™ Annexin V kits, BD Phamingen BrdU kits, and antibodies to cyclins and activated caspases optimized for use on BD flow cytometry systems.